Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 54.47B | 52.03B | 51.61B | 52.32B | 51.03B |
Gross Profit | 8.45B | 8.13B | 8.12B | 8.07B | 7.44B |
EBITDA | 1.38B | 2.66B | 2.83B | 2.59B | 2.26B |
Net Income | -351.00M | 333.00M | 447.00M | 426.00M | 577.00M |
Balance Sheet | |||||
Total Assets | 29.49B | 23.42B | 23.75B | 24.72B | 25.21B |
Cash, Cash Equivalents and Short-Term Investments | 7.15B | 4.74B | 3.99B | 4.60B | 4.47B |
Total Debt | 12.75B | 9.14B | 9.91B | 10.70B | 11.23B |
Total Liabilities | 22.05B | 16.43B | 17.05B | 18.39B | 19.26B |
Stockholders Equity | 7.36B | 6.88B | 6.61B | 6.22B | 5.91B |
Cash Flow | |||||
Free Cash Flow | 2.10B | 1.98B | 247.00M | 1.39B | 1.11B |
Operating Cash Flow | 2.71B | 2.52B | 713.00M | 1.95B | 1.57B |
Investing Cash Flow | -3.12B | -703.00M | -292.00M | -1.08B | -734.00M |
Financing Cash Flow | 2.77B | -1.07B | -1.03B | -728.00M | -766.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥16.12B | 6.04 | 2.22% | 4.42% | 20.59% | ||
74 Outperform | ¥45.80B | 10.42 | 1.21% | 6.65% | 12.77% | ||
70 Outperform | ¥14.40B | 11.05 | 2.51% | 6.09% | -30.07% | ||
65 Neutral | CHF27.48B | 16.45 | 9.37% | 2.26% | 30.32% | 7.54% | |
65 Neutral | ¥11.50B | 15.02 | 1.20% | 4.87% | 63.01% | ||
62 Neutral | ¥5.85B | ― | 2.81% | 16.60% | -19.16% | ||
60 Neutral | ¥19.65B | 8.67 | 3.70% | 12.75% | -191.21% |
Pharmarise Holdings Corporation reported a significant increase in net sales for the first nine months of the fiscal year ending May 31, 2025, with a 14.5% year-on-year growth. However, the company faced challenges with a substantial decline in operating profit and a net loss attributable to the owners, indicating potential operational difficulties. The financial results reflect a complex market environment, and the company has made changes in accounting policies and added a new company to its consolidation scope, which may impact future performance.